June 11, 2026 · 7 min read

Bupropion’s Seizure Risk Is the Board-Exam Trap Hiding in Your Most-Prescribed Antidepressant — Here’s What Every PMHNP Student Needs to Know

A single amber prescription bottle tipped on its side spilling small white tablets across dark slate

Imagine the patient sitting across from you in clinic. She’s 26, exhausted by depression, and she’s heard that one antidepressant out there won’t blunt her libido or pile on weight. She’s right — that drug is bupropion, and it’s a genuinely good one. But buried in her chart is a line she mentioned almost in passing: a few years of “controlling her eating” in college that involved purging. You’re about to reach for a prescription that, in her specific case, could trigger a seizure. Do you catch it? On the boards, and in real life, that single decision is the difference between a competent psychiatric mental health nurse practitioner and one who hurt a patient with a routine drug.

Bupropion — you’ll know it as Wellbutrin, and in its smoking-cessation packaging as Zyban — is one of the most widely prescribed antidepressants in the country, and for good reasons. But it carries a seizure risk that is dose-dependent, predictable, and absolutely testable. This is exactly the kind of topic boards adore, because it rewards the student who actually understands the pharmacology instead of memorizing a drug name and a vibe. Let’s own it cold.

Why bupropion is everywhere — and why that’s the trap

Start with why this drug is so popular, because its strengths are the reason its risks get overlooked. Bupropion is a norepinephrine-dopamine reuptake inhibitor, which makes it pharmacologically different from the serotonin-driven SSRIs and SNRIs that dominate prescribing. That mechanism gives it a profile patients love: it’s activating rather than sedating, it doesn’t typically cause sexual dysfunction, and it tends to be weight-neutral or even cause modest weight loss. It’s a workhorse for depression, a first-line aid for smoking cessation, and a common add-on to take the edge off SSRI-induced sexual side effects. On the Carlat Psychiatry Podcast, Dr. Chris Aiken, editor-in-chief of The Carlat Psychiatry Report, has repeatedly highlighted bupropion as one of the better-tolerated antidepressants for exactly these reasons.

Here’s the catch. When a drug is this comfortable to prescribe and this familiar, clinicians get casual with it. And bupropion is the one common antidepressant where casual prescribing can produce a convulsion. The whole skill is holding two ideas at once: this is a friendly, well-tolerated medication, and it lowers the seizure threshold more than its peers. Both are true. The expertise lives in respecting the second fact without abandoning the first.

The seizure mechanism and the numbers you must know

Bupropion lowers the seizure threshold in a dose-dependent way — push the dose up, and the risk climbs with it. This is the single most important sentence in this entire article, so let it sink in. The numbers tell the story cleanly, and they’re worth memorizing because exam writers love them.

With the original immediate-release (IR) formulation, the FDA prescribing information and StatPearls both put the seizure incidence at roughly 0.4% — about 0.35% to 0.44% — at doses up to 450 mg per day. That’s roughly four in every thousand patients, which is far higher than you’d tolerate from a routine antidepressant. The reformulations were a direct response to that problem. The sustained-release (SR) and extended-release (XL) versions smooth out the peak plasma concentrations, and they drop the seizure rate down to about 0.1% — one in a thousand — when kept at or below 300 mg per day. That is the reason almost nobody prescribes plain IR bupropion at high doses anymore.

Now the number that turns into board questions: the risk doesn’t rise gently. According to the FDA labeling, the seizure incidence increases almost ten-fold between 450 mg and 600 mg per day. Cross that ceiling, whether through a prescribing error, a patient doubling up, or stacking two bupropion products, and you’ve moved from a low-probability event into genuinely dangerous territory. The dose ceiling isn’t bureaucratic caution — it’s the edge of a cliff.

An overhead flat lay of a weekly pill organizer, a glass of water and folded reading glasses on white linen

The contraindications boards build entire questions around

If you take nothing else from this piece, take these three contraindications, because they are the classic bupropion vignette and they show up again and again. The FDA prescribing information lists them plainly.

First, a seizure disorder of any kind. Giving a threshold-lowering drug to someone who already seizes is the most obvious mistake, which is exactly why exam writers like to bury it in a paragraph about an otherwise perfect candidate for bupropion.

Second — and this is the one that trips people up — a current or prior diagnosis of bulimia or anorexia nervosa. Note the wording: current or prior. It’s not “only if they’re actively purging.” A history counts. The reason is that patients with eating disorders showed a markedly higher seizure rate in the early bupropion trials, likely tied to electrolyte disturbances, low body weight, and purging behavior. This is the trap I opened with, and it’s a favorite precisely because the rest of the patient — young, depressed, worried about weight gain and sexual side effects — looks like a textbook bupropion candidate until you spot that one line in the history.

Third, abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs. Each of these withdrawal states independently lowers the seizure threshold, and layering bupropion on top compounds the danger. So the patient with alcohol use disorder who’s drying out, or the one tapering off a benzodiazepine, is not who you start on bupropion that week.

Worth filing alongside these: anything else that drops the threshold raises the stakes. Other medications that lower the seizure threshold, conditions like head trauma or CNS tumors, and stimulant use all stack risk. Good prescribing is additive arithmetic — you’re always asking what else in this patient’s picture is nudging the threshold down before you add a drug that nudges it further.

The dosing rules that keep patients safe

Knowing the contraindications gets you halfway. The other half is dosing discipline, because most bupropion seizures in stable patients trace back to a dose or a schedule that drifted past the safety margins. The ceilings are non-negotiable and very memorizable.

Immediate-release bupropion maxes out at 450 mg per day, given as 150 mg three times daily, and no single dose should exceed 150 mg. The reason for splitting it matters: it’s the peak concentration that provokes seizures, so you spread the doses out — generally at least four to six hours apart — to keep any single peak low. Sustained-release tops out at 400 mg per day, typically dosed as 200 mg twice daily. Extended-release goes up to 450 mg per day in a single morning dose. Memorize those three ceilings as a set, because mixing them up is precisely the error a question will test.

Two practical landmines deserve a flag. The first is accidental stacking. A patient may be on bupropion XL for depression and then get prescribed bupropion (as Zyban) for smoking cessation by a different clinician — now they’re double-dosed and possibly over 450 mg without anyone intending it. Reconciling medications across prescribers isn’t busywork; here it prevents a seizure. The second is the food-and-formulation gotcha: every formulation must be swallowed whole. A crushed or chewed extended-release tablet dumps its entire load at once, recreating the dangerous peak the formulation was designed to prevent.

A smooth grey stone balanced at the edge of a dark ledge above a shadowed void in golden backlight

Overdose: where this gets acutely dangerous

Therapeutic dosing is one conversation; overdose is another, and it’s where bupropion turns genuinely scary. This matters more than ever because bupropion is frequently prescribed to depressed patients — the exact population at elevated risk for intentional overdose. Toxicology resources have been sounding this alarm with fresh urgency: the StatPearls chapter on bupropion toxicity was updated in February 2026, and emergency-medicine education outlets like the NUEM Blog published new reviews this spring reinforcing how dangerous these ingestions are.

The clinical picture you need to recognize: bupropion overdose causes tachycardia, agitation, and seizures, and the seizures can be delayed — appearing hours after ingestion, sometimes when the patient looks deceptively stable, particularly with the extended-release formulations that keep releasing drug over time. Retrospective studies cited in StatPearls report seizure rates in overdose ranging widely, and large ingestions can progress to status epilepticus, cardiac conduction abnormalities, and malignant arrhythmias. There is no antidote. Management is supportive — controlling seizures, protecting the airway, cardiac monitoring, and a prolonged observation window precisely because of that delayed-seizure risk. For a PMHNP, the takeaways are practical: weigh quantity prescribed and refill size against overdose risk in someone with suicidal ideation, and counsel families about safe storage.

Why this matters for you, specifically

Here’s the thing about bupropion’s seizure risk: it’s the perfect microcosm of what your boards — and your future patients — actually demand from you. It’s not asking you to memorize a fact in isolation. It’s asking you to hold a drug’s benefits and its dangers in the same hand, to read a patient’s history for the one detail that flips the whole picture, and to respect a dose ceiling because you understand the pharmacology behind it. That’s not test-taking. That’s clinical judgment, and it’s the exact skill that makes a prescriber safe.

So when you see a bupropion question on the ANCC or AANP exam — and you will — slow down and run the checklist. Any seizure history? Any eating disorder, ever? Any acute withdrawal from alcohol or sedatives? What’s the total daily dose, and across how many prescriptions? If you can run that scan automatically, you’ve already separated yourself from the prescriber who reaches for the friendly antidepressant without looking twice. Master the few drugs where the margin for error is thin, and you become the clinician patients can actually trust.

You came into this field to help the people everyone else finds complicated. Owning the details on a drug like bupropion — really owning them — is how you earn that trust, one safe prescription at a time. If you’re ready to turn this kind of high-yield, board-tested pharmacology into the confidence you’ll carry into your exam and your first clinic, that’s exactly what we build at PMHNPReview.org. Come study with us, and let’s make these the questions you can’t wait to see.